Syda Productions / Shutterstock.com
The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins.
The pharmaceutical industry is becoming increasingly interested in digital health and serious money is being invested in the technology.
For example, Roche has invested in mySugr, a company that offers an app to help patients manage their diabetes, and Propeller Health is a company working on connected inhaler technology with GSK, Aptar and Boehringer Ingelheim.
Pharmaceutical companies are used to an established commercial formula for bringing new products to market, with product development involving a significant up-front investment including research and development costs and generating the requisite quality, safety and efficacy data.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Hogan Lovells, RGC Jenkins, Stephen Bennett, Elisabethann Wright, Mark Marfe, trademark, digital age, European Commission, patent, MA,
